Old wine in new wineskins. Hamman-Rich syndrome has much in common with severe COVID-19: Do they share any link of pathogenesis or depend on the similar aetiological factor(s)?*

Яна Ивашкевич; Александр  Коровин; Алина Петяева; Леонид Чурилов

doi:10.21638/spbu11.2020.201

Авторы

Яна Ивашкевич St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Александр Коровин St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Алина Петяева St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
Леонид Чурилов St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ; St. Petersburg Research Institute of Phthisiopulmonology, Health Ministry of Russia, 2–4, Ligovskiy pr., St. Petersburg, 191036, Russian Federation

DOI:

https://doi.org/10.21638/spbu11.2020.201

Аннотация

For the first time the acute interstitial pneumonitis as a main cause of adult idiopathic respiratory distress syndrome was described in 1933–35 by the American medical scholars Louis Virgil Hamman and Arnold Rice Rich as “acute fibrosing alveolitis” later given the eponymous name Hamman-Rich syndrome. This disease targets the interstitium of the lungs and characterized by fulminant onset, acute respiratory disorder with possibility of respiratory failure, being clinically similar to respiratory distress syndrome with the pathomorphologically revealed diffuse alveolar damage. Hamman-Rich syndrome is characterized by rapid progression from symptoms of common cold such as cough, fever, chills and dyspnea to severe respiratory failure. The syndrome affects apparently healthy individuals and is not associated with any anamnestic chronic lung diseases, smoking habits, neither with patients’ age or sex. The aetiology and pathogenesis of the Hamman-Rich syndrome are not clear yet. The familiar genetic predisposition is of definite meaning, especially related to mutations of surfactant proteins and their metabolism. The possible mechanistic links of this fulminant lung disease involve: NK-cells, auto-aggressive immune activation and certain types of cytokines during their excessive systemic action, so-called cytokine storm (e.g. interleukin-18 and interleukin-2), which play the leading part in the patho-genesis of acute lung cell injury resulting in diffuse non-remitting pneumofibrosis. But all these clinical and pathogenetic features are also common for severe COVID-19. Computed tomography is used for instrumental diagnosis of Hamman-Rich syndrome and also gives the lung images quite similar to that of COVID-19, including ground glass opacity symptoms. The authors hypothesize that the same link(s) of pathogenesis underlie the severe course of COVID-19 and Hamman-Rich syndrome. It is possible that cases of Hamman-Rich syndrome were due to the circulation in populations of a less virulent, unrecognized coronavirus, which interacts with the immune system of genetically susceptible individuals in a way similar to SARS-CoV2. For sure, the identification of the characteristics of the genome of patients with Hamman-Rich syndrome will shed light on the genetic mechanisms that predispose to the severe course of COVID-19 and vice versa — the experience of severe COVID-19 treatment can be applied to the therapy of Hamman-Rich syndrome as well.

Ключевые слова:

autoimmunity, acute fibrosing alveolitis, acute interstitial pneumonia, COVID-19, Hamman-Rich syndrome, acute respiratory distress syndrome, cytokine storm, complement C3, interleukin-18, macrophages, natural killers, surfactant proteins

Скачивания

Данные скачивания пока недоступны.

Библиографические ссылки

References

Yuki K., Fujiogi M., Koutsogiannaki S. COVID-19 pathophysiology: A review.Clin Immunol. 2020,vol. 215, 108427. https://doi.org/10.1016/j.clim.2020.108427.

Zhou G., Chen S., Chen Z. Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies.Front Med.2020, vol. 14, no. 2, pp. 117–125. https://doi.org/10.1007/s11684-020-0773-x.

Ehrenfeld M., Tincani A., Andreoli L., Cattalini M., Greenbaum A., Kanduc D., Alijotas-Reig J., Zinserling V., Semenova N., Amital H., Shoenfeld Y. COVID-19 and autoimmunity.Autoimmun Rev. 2020, vol. 19, no. 8, 102597. https://doi.org/10.1016/j.autrev.2020.10259.

Mrad A., Huda N. Acute Interstitial Pneumonia. 2020 Aug 11. StatPearls [Internet]. Treasure Island (FL), StatPearls Publishing; 2020. Jan–. PMID: 32119316.

Mastan A., Murugesu N., Hasnain A., O’Shaughnessy T., Macavei V. Hamman-Rich syndrome. Respir Med Case Rep.2017, vol. 23, pp. 13–17. https://doi.org/10.1016/j.rmcr.2017.10.008.

Zhang W., Zhao Y., Zhang F., Wang Q., Li T., Liu Z., Wang J., Qin Y., Zhang X., Yan X., Zeng X., Zhang S. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.Clin Immunol.,2020, vol. 214, 108393. https://doi.org/10.1016/j.clim.2020.108393.

Katzenstein A. L., Myers J. L., Mazur M. T. Acute interstitial pneumonia. A clinicopathologic, ultrastructural,and cell kinetic study. Am J Surg Pathol., 1986, vol. 10, no. 4, pp. 256–267.

Katzenstein A. L., Myers J. L., Prophet W. D., Corley L. S. 3rd, Shin M. S. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study.Am J Surg Pathol.,1986, vol. 10, no. 6, pp. 373–381. https://doi.org/10.1097/00000478–198606000-00002.

Severiche Bueno D. F., Vargas Cuervo M. T., Severiche Hernández D. L., Cerchiaro D. M., Hernandez H. S., Benigni E. M., Severiche Bueno D. F. Neumonía intersticial aguda o síndrome de Hamman 104 Rich. Reporte de un caso.Acta Colombiana de Cuidado Intensivo,2018, vol. 18, no. 4, pp. 255–260.https://doi.org/10.1016/j.acci.2018.06.004.

Newmarch W., Puopolo A., Weiler M., Casserly B. Hamman-Rich syndrome: a forgotten entity.Monaldi Arch Chest Dis.2017, vol. 87, no. 1, 799 p. https://doi.org/10.4081/monaldi.2017.799.

Mukhopadhyay S., Parambil J. G. Acute interstitial pneumonia (AIP): relationship to Hamman-Rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS). Semin Respir Crit Care Med., 2012, vol. 33, no. 5, pp. 476–485. https://doi.org/10.1055/s-0032–1325158.

Vieira F. V., Custódio F. B., Meneses A. C. O. Pneumonia intersticial aguda (síndrome de Hamman-Rich): relato de caso e revisão de literatura. Rev Soc Bras Clin Med., 2016, vol. 14, no. 1, pp. 45–47.

Lemle A., Pubens J., Vieira L. O. Fibrose pulmonar difusa idiopática — possível síndrome de Hamman-Rich. Apresentação de um caso com exploração funcional pulmonar. Rev Bras Med., 1968, vol. 25,no. 2, pp. 85–91.

Thomas H., Costabel U. Progredient verlaufende idiopathische Lungenfibrose bei zwei eineiigen Zwillingsschwestern. Pneumologie 1996, vol. 50, no. 9, pp. 679–682.

Appelman A. C., Buytendijk H. J. Chronische interstitiële longontsteking (Hamman-Rich syndroom) in een gezin. Ned Tijdschr Geneeskd., 1961, vol. 105, pp. 1928–1930.

Bariş I., Atrvinli M., Ozesmi M. Familyal Hamman-Rich sendromu. Turk Tip Dernegi Derg., 1973,vol. 39, no. 9, pp. 330–337.

Touloukian J. S. A familial variant of the Hamman-Rich syndrome. J Indiana State Med Assoc., 1975, vol. 68, no. 11, pp. 956–958.

Vogel C., Scheibe F. W. Zur frage des Hamman-Rich-syndroms im kindesalter (diffuse und nodulaere lungengeruesterkrankung bei 2 geschwistern). Kinderarztliche Praxis., 1963, vol. 31, pp. 285–292.

Gabitova N. K., Cherezova I. N., Cherezova K. A. Idiopatic fibrosing alveolitis in a newborn. Rossiiskii Vestnik Perinatologii i Pediatrii, 2019, vol. 64, no. 5, pp. 226–229. (In Russian)

Zinchenko R. A., Murzabaeva S. Sh., Grinberg Ya. I., Galkina V. A., Bessonova L. A., Dadali E. L., Khlebnikova O. V., Khidiyatova I. M., Grinberg E. R., Fedotov V. P., Elchinova G. I., Shchagina O. A.,Polyakov A. V., Khusnutdinova E. K., Ginter E. K. Medical genetic study of the population of the Republic of Bashkortostan. Proceeding IX. Factors of population dynamics that determine the values of the burden of monogenic hereditary diseases. Med. Genetics, 2009, vol. 8, no. 5, pp. 11–23. (In Russian)

Mizernitsky Y. L., Rozinova N. N., Sokolova L. V., Bogorad A. E., Gryazina O. V. Rare lung diseases in children — an actual pulmonology problem. Rossiiskii Vestnik Perinatologii i Pediatrii, 2012, vol. 57, no. 4–1, pp. 44–49. (In Russian)

Peabody J. W., Peabody J. W. Jr., Hayes E. W., Hayes E. W. Jr. Idiopathic pulmonary fibrosis; its occurrence in identical twin sisters.Dis Chest., 1950, vol. 18, no. 4, pp. 330–344. https://doi.org/10.1016/s0096-0217(15)34710–5.

Donohue W. L., Laski B., Uchida I. A., Munn J. D. Familial fibrocystic pulmonary dysplasia and its relation to the Hamman-Rich syndrome.Pediatrics, 1959, vol. 24, pp. 786–813.

Young W. A. Familial fibrocystic pulmonary dysplasia: a new case in a known affected family. Canad. Med. Assoc. J., 1966, vol. 94, pp. 1059–1061.

Swaye P., Van Ordstrand H. S., McCormack L. J., Wolpaw S. E. Familial Hamman-Rich syndrome. Report of eight cases. Dis Chest., 1969, vol. 55, no. 1, pp. 7–12. https://doi.org/10.1378/chest.55.1.7.

Thomas A. Q., Lane K., Phillips J. 3rd, Prince M., Markin C., Speer M., Schwartz D. A., Gaddipati R.,Marney A., Johnson J., Roberts R., Haines J., Stahlman M., Loyd J. E. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med., 2002, vol. 165, no. 9, pp. 1322–1328.https://doi.org/10.1164/rccm.200112–123OC.

Nathan N., Berdah L., Delestrain C., Sileo C., Clement A. Interstitial lung diseases in children. Presse Med., 2020, vol. 49, no. 2, 103909. https://doi.org/10.1016/j.lpm.2019.06.007.

Nathan N., Sileo C., Thouvenin G., Berdah L., Delestrain C., Manali E., Papiris S., Léger P. L., Pointe H. D. L., l’Hermine A. C., Clement A. Pulmonary Fibrosis in Children. J Clin Med., 2019, vol. 8, no. 9, 1312. https://doi.org/10.3390/jcm8091312.

Nathan N., Berdah L., Borensztajn K., Clement A. Chronic interstitial lung diseases in children: diagnosis approaches. Expert Rev Respir Med., 2018, vol. 12, no. 12, pp. 1051–1060. https://doi.org/10.1080/17476348.2018.1538795.

Leshchenko I. V., Zherebtsov A. D. Idiopathic pulmonary fibrosis: modern view of pathogenesis and the role of biomarkers. RMJ, 2018, vol. 10, no. 1, pp. 6–10. (In Russian)

Clement A., de Blic J., Epaud R., Galeron L., Nathan N., Hadchouel A., Barbato A., Snijders D., Kiper N., Cunningham S., Griese M., Bush A., Schwerk N. Management of children with interstitial lung diseases: the difficult issue of acute exacerbations. Eur Respir J., 2016, vol. 48, no. 6, pp. 1559–1563.https://doi.org/10.1183/13993003.01900–2016.

Clement A., Nathan N., Epaud R., Fauroux B., Corvol H. Interstitial lung diseases in children. Orphanet J Rare Dis., 2010, vol. 5, p. 22. https://doi.org/10.1186/1750–1172–5–22.

Plasek J., Dvoračkova J., Jahoda J., Trulikova K., Mokosova R., Danek T., Hrabovsky V., Martinek A. Acute interstitial pneumonia (Hamman-Rich syndrome) in idiopathic pulmonary fibrosis and bronchoalveolar carcinoma: a case report. Biomed Pap Med Fac Univ Palacky (Olomouc Czech Repub), 2011, vol. 155, no. 4, pp. 403–407. https://doi.org/10.5507/bp.2011.039.

Minenkova T. A., Mizernitskiy Yu. L., Razinkova N. S., Serezhkina A. V., Kostyuchenko M. V. Hamman-Rich syndrome in a young child. Rossiiskii Vestnik Perinatologii i Pediatrii, 2019, vol. 64, no. 4, pp. 83–87. (In Russian)

Chertoff J., Alnuaimat H. A 45-Year-Old Woman with Acute Interstitial Pneumonia (Hamman-Rich Syndrome). Turk J Anaesthesiol Reanim., 2017, vol. 45, no. 4, p. 244. https://doi.org/10.5152/TJAR.2017.98105.

Fujita J., Tohyama M., Haranaga S., Cash H. L., Higa F., Tateyama M. Hamman-Rich syndrome revisited:how to avoid misdiagnosis. Influenza Other Respir Viruses, 2013, vol. 7, no. 1, pp. 4–5. https://doi.org/10.1111/j.1750–2659.2012.00353.x.

Stroev Y. I., Churilov L. P. Diagnosis of the Diseases of Respiratory System and Its Pathophysiological Basis: III. Cor Pulmonale — Pulmonary Heart Disease. Russian Biomedical Research, 2020, vol. 5,no. 2, pp. 4–16.

Feshhenko Ju. I., Gavrisjuk V. K., Monogarova N. E., Jachnik A. I. Idiopathic fibrosing alveolitis as a form of idiopathic interstital pneumonia. Ukraїns’kii pul’monologіchnii zhurnal, 2004, vol. 4, pp. 5–11. (In Russian)

Hewitt C. J., Hull D., Keeling J. W. Fibrosing alveolitis in infancy and childhood. Arch Dis Child., 1977,vol. 52, no. 1, pp. 22–37. https://doi.org/10.1136/adc.52.1.22.

Sharief N., Crawford O. F., Dinwiddie R. Fibrosing alveolitis and desquamative interstitial pneumonitis. Pediatr Pulmonol.,1994, vol. 17, no. 6, pp. 359–365. https://doi.org/10.1002/ppul.1950170604.

Bruminhent J., Yassir S., Pippim J. Acute interstitial pneumonia (Hamman-Rich syndrome) as a cause of idiopathic acute respiratory distress syndrome. Case Rep Med., 2011, vol. 2011, 628743. https://doi.org/10.1155/2011/628743.

Avnon L. S., Pikovsky O., Sion-Vardy N., Almog Y. Acute interstitial pneumonia-Hamman-Rich syndrome:clinical characteristics and diagnostic and therapeutic considerations. Anesth Analg., 2009,vol. 108, no. 1, pp. 232–237. https://doi.org/10.1213/ane.0b013e318188af7a.

Hamid S., Mir M. Y., Rohela G. K. Novel coronavirus disease (COVID-19): a pandemic (epidemiology,pathogenesis and potential therapeutics).New Microbes New Infect., 2020, vol. 35, 100679. https://doi.org/10.1016/j.nmni.2020.100679.

Harapan H., Itoh N., Yufika A., Winardi W., Keam S., Te H., Megawati D., Hayati Z., Wagner A. L., Mudatsir M. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health, 2020,vol. 13, no. 5, pp. 667–673. https://doi.org/10.1016/j.jiph.2020.03.019.

Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect., 2020, vol. 80, no. 6, pp. 607–613. https://doi.org/10.1016/j.jinf.2020.03.037.

Mastaglio S., Ruggeri A., Risitano A. M., Angelillo P., Yancopoulou D., Mastellos D. C., Huber-Lang M., Piemontese S., Assanelli A., Garlanda C., Lambris J. D., Ciceri F. The first case of COVID-19 treated with the complement C3 inhibitor AMY–101. Clin Immunol., 2020, vol. 215, 108450. https://doi.org/10.1016/j.clim.2020.108450.

Wootton S. C., Kim D. S., Kondoh Y., Chen E., Lee J. S., Song J. W., Huh J. W., Taniguchi H., Chiu C.,Boushey H., Lancaster L. H., Wolters P. J., DeRisi J., Ganem D., Collard H. R. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med., 2011, vol. 183, no. 12, pp. 1698–1702. https://doi.org/10.1164/rccm.201010–1752OC.

Azadeh N., Limper A. H., Carmona E. M., Ryu J. H. The Role of Infection in Interstitial Lung Diseases: A Review. Chest, 2017, vol. 152, no. 4, pp. 842–852.

Sawalha A. H., Zhao M., Coit P., Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol., 2020, vol. 215, 108410. https://doi.org/10.1016/j.clim.2020.108410.

Rautenstrauch H. Diffuse interstitielle Lungenfibrose (Hamman-Rich-Syndrom) und primär chronische Polyarthritis. Z Gesamte Inn Med., 1971, vol. 26, no. 1, pp. 39–41.

Pratt D. S., Schwartz M. I., May J. J., Dreisin R. B. Rapidly fatal pulmonary fibrosis: the accelerated variant of interstitial pneumonitis. Thorax, 1979, vol. 34, no. 5, pp. 587–593. https://doi.org/10.1136/thx.34.5.5874.

Vojinovic T., Cavazzana I., Ceruti P., Fredi M., Modina D., Berlendis M., Franceschini F. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. Clin Rev Allergy Immunol.,2020. November 3rd [E-pub ahead of print]. https://doi.org/10.1007/s12016-020-08814–5.

Ryabkova V. A., Shubik Y. V., Erman M. V., Churilov L. P., Kanduc D., Shoenfeld Y. Lethal immunoglobulins:Autoantibodies and sudden cardiac death. Autoimmun Rev., 2019, Apr. 18, vol. 4, pp. 415–425. https://doi.org/10.1016/j.autrev.2018.12.005.

Fassihi H., Wong T., Wessagowit V., McGrath J. A., Mellerio J. E. Target proteins in inherited and acquired blistering skin disorders. Clin Exp Dermatol., 2006, vol. 31, no. 2, pp. 252–259. https://doi.org/10.1111/j.1365–2230.2006.02065.x.

McKusik V. A., Kniffin C. L. OMIM *178620. Surfactant, Pulmonary Associated Protein C, SFTPC.Available at: https://www.omim.org/entry/ 178620#22 (accessed: 03.11.2020).

Kanduc D., Shoenfeld Y. On the molecular determinants of the SARS-CoV-2 attack. Clin Immunol.,2020, vol. 215, 108426. https://doi.org/10.1016/j.clim.2020.108426.

Vojdani A., Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol., 2020, vol. 217, 108480.https://doi.org/10.1016/j.clim.2020.108480.

Han Y., Jiang M., Xia D., He L., Lv X., Liao X., Meng J. COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster. Clin Immunol., 2020, vol. 214, 108413. https://doi.org/10.1016/j.clim.2020.108413.

Felsenstein S., Herbert J. A., McNamara P. S., Hedrich C. M. COVID-19: Immunology and treatment options. Clin Immunol., 2020, vol. 215, 108448. https://doi.org/10.1016/j.clim.2020.108448.

Obasi J. An Elusive Case of Acute Interstitial Pneumonia. Cureus., 2019, vol. 11, no. 5, e4685. https://doi.org/10.7759/cureus.4685.

Zhang Q., Raza A., Chan V., Minalyan A., Madara J. Hamman-Rich Syndrome: A Diagnosis of Exclusion in the COVID-19 Pandemic. Cureus, 2020, vol. 12, no. 8, e9866. https://doi.org/10.7759/cureus.9866.

Conti L., Zammit C. Incidental tracheal bronchus in a case of Hamman-Rich syndrome. BMJ Case Rep., 2019, vol. 12, no. 5, e229579. https://doi.org/10.1136/bcr–2019–229579.

Hubbard R., Johnston I., Coultas D. B., Britton J. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax., 1996, vol. 51 (7), pp. 711–716. https://doi.org/10.1136/thx.51.7.711.

Hamman L., Rich A. R. A clinical-pathological conference. A case of heart failure. International Clinics, 43rd series, 1933, vol. 1, pp. 197–232.

Hamman L., Rich A. R. Fulminating Diffuse Interstitial Fibrosis of the Lungs. Trans Am Clin Climatol Assoc., 1935, vol. 51, pp. 154–163.

Hamman L., Rich A. R. Acute diffuse interstitial fibrosis of the lungs. Bulletin of the Johns Hopkins Hospital, (Baltimore), 1944, vol. 74, pp. 177–212.